WallStreetZenWallStreetZen

NASDAQ: SURG
Surgepays Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SURG

Based on 1 analyst offering 12 month price targets for Surgepays Inc

Min Forecast
$3.50+1,520.37%
Avg Forecast
$3.50+1,520.37%
Max Forecast
$3.50+1,520.37%

Should I buy or sell SURG stock?

Based on 1 analyst offering ratings for Surgepays Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SURG stock forecasts and price targets.

SURG stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-10

1 of 1

Forecast return on equity

Is SURG forecast to generate an efficient return?

Company
-5.38%
Industry
95.54%
Market
136.16%
SURG's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SURG forecast to generate an efficient return on assets?

Company
13.48%
Industry
33.46%
SURG is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SURG earnings per share forecast

What is SURG's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.71
Avg 2 year Forecast
$0.05

SURG revenue forecast

What is SURG's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$66.3M+6.3%
Avg 2 year Forecast
$81.7M+31%
SURG's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SURG revenue growth forecast

How is SURG forecast to perform vs Software - Application companies and vs the US market?

Company
6.3%
Industry
21.01%
Market
22.03%
SURG's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SURG's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SURG vs App Stocks

TickerPricePrice TargetUp/downsideConsensus
SURG$0.22$3.50+1,520.37%Buy
AUUD$1.05N/AN/A
AMST$0.98N/AN/A
AMOD$3.74$15.00+301.07%Strong Buy
ORKT$1.01N/AN/A
View Top App Stocks

Surgepays Stock Forecast FAQ

Is Surgepays Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SURG) stock is to Buy SURG stock.

Out of 1 analyst, 0 (0%) are recommending SURG as a Strong Buy, 1 (100%) are recommending SURG as a Buy, 0 (0%) are recommending SURG as a Hold, 0 (0%) are recommending SURG as a Sell, and 0 (0%) are recommending SURG as a Strong Sell.

If you're new to stock investing, here's how to buy Surgepays stock.

What is SURG's earnings growth forecast for 2026-2027?

(NASDAQ: SURG) Surgepays's forecast annual earnings growth rate of N/A is not forecast to beat the US Software - Application industry's average forecast earnings growth rate of 101.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,398.91%.

Surgepays's earnings in 2026 is -$40,484,669.On average, 3 Wall Street analysts forecast SURG's earnings for 2026 to be -$17,937,033, with the lowest SURG earnings forecast at -$17,233,620, and the highest SURG earnings forecast at -$18,464,593.

In 2027, SURG is forecast to generate $1,281,217 in earnings, with the lowest earnings forecast at $1,230,973 and the highest earnings forecast at $1,318,899.

What is SURG's revenue growth forecast for 2026-2027?

(NASDAQ: SURG) Surgepays's forecast annual revenue growth rate of 6.3% is not forecast to beat the US Software - Application industry's average forecast revenue growth rate of 21.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.03%.

Surgepays's revenue in 2026 is $62,369,473.On average, 3 Wall Street analysts forecast SURG's revenue for 2026 to be $1,665,581,639, with the lowest SURG revenue forecast at $1,600,264,712, and the highest SURG revenue forecast at $1,714,569,334.

In 2027, SURG is forecast to generate $2,052,509,065 in revenue, with the lowest revenue forecast at $1,972,018,514 and the highest revenue forecast at $2,112,876,979.

What is SURG's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: SURG) forecast ROA is 13.48%, which is lower than the forecast US Software - Application industry average of 33.46%.

What is SURG's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SURG price target, the average SURG price target is $3.50, with the highest SURG stock price forecast at $3.50 and the lowest SURG stock price forecast at $3.50.

The Wall Street analyst predicted that Surgepays's share price could reach $3.50 by Jun 10, 2027. The average Surgepays stock price prediction forecasts a potential upside of 1,520.37% from the current SURG share price of $0.22.

What is SURG's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: SURG) Surgepays's current Earnings Per Share (EPS) is -$1.94. On average, analysts forecast that SURG's EPS will be -$0.71 for 2026, with the lowest EPS forecast at -$0.69, and the highest EPS forecast at -$0.74. In 2027, SURG's EPS is forecast to hit $0.05 (min: $0.05, max: $0.05).

What is SURG's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: SURG) forecast ROE is -5.38%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.